Celecoxib
Rank #188 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$77.7M
Total Cost
1,938,505
Total Claims
$77.7M
Total Cost
49,891
Prescribers
$40
Cost per Claim
517,820
Beneficiaries
3,127,826
30-Day Fills
$1,556
Avg Cost/Provider
39
Avg Claims/Provider
Share of Medicare Part D Spending
0.03%
of total Medicare Part D spending
$77.7M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $77.7M total
Top Prescribers of Celecoxib
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Najmuddin Karimjee | Internal Medicine | Houston, TX | 1,059 | $88K |
| 2 | Anthony Jung | Internal Medicine | Flushing, NY | 2,103 | $81K |
| 3 | Steven Nguyen | Family Practice | Houston, TX | 168 | $80K |
| 4 | Mark Hsiao | Orthopedic Surgery | Alhambra, CA | 1,696 | $78K |
| 5 | Mai Phan | Internal Medicine | Reseda, CA | 354 | $78K |
| 6 | Christopher Labonte | Internal Medicine | Town And Country, MO | 1,228 | $77K |
| 7 | Mark Song | Internal Medicine | Los Angeles, CA | 1,005 | $75K |
| 8 | Farhad Kadkhodaei Elyaderani | Neurology | Bronx, NY | 69 | $61K |
| 9 | Rita Goldvug | Internal Medicine | Rego Park, NY | 58 | $59K |
| 10 | Lyubov Moysik | Family Practice | Brooklyn, NY | 846 | $57K |
| 11 | Bachar Malek | Internal Medicine | Evansville, IN | 214 | $57K |
| 12 | Philip Merritt | Orthopedic Surgery | Glendale, CA | 1,067 | $56K |
| 13 | Armando Hassun | Interventional Pain Management | Coral Gables, FL | 4,309 | $51K |
| 14 | Thuan Vo | Internal Medicine | Westminster, CA | 1,097 | $50K |
| 15 | Jose Bautista | Internal Medicine | Sanger, CA | 421 | $49K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 185 | Insulin Nph Hum/Reg Insulin Hm (Humulin 70-30) | $82.3M | 177,501 |
| 186 | Montelukast Sodium (Montelukast Sodium) | $81.3M | 5,086,706 |
| 187 | Certolizumab Pegol (Cimzia) | $79.9M | 11,784 |
| 188 | Celecoxib (Celecoxib) | $77.7M | 1,938,505 |
| 189 | Sod Phenylbutyrat/Taurursodiol (Relyvrio) | $77.0M | 6,152 |
| 190 | Pravastatin Sodium (Pravastatin Sodium) | $76.8M | 4,033,829 |
| 191 | Lanadelumab-Flyo (Takhzyro) | $76.5M | 1,670 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology